A revisit of prophylactic lamivudine for chemotherapy‐associated hepatitis B reactivation in non‐Hodgkin's lymphoma: A randomized trial
Chiun Hsu, Chao A. Hsiung, Ih‐Jen Su, Wei‐Shou Hwang, Ming‐Chung Wang, Sheng‐Fung Lin, Tseng‐Hsi Lin, Hui‐Hua Hsiao, Ji‐Hsiung Young, Ming‐Chih Chang, Yu‐Min Liao, Chi‐Cheng Li, Hung‐Bo Wu, Hwei‐Fang Tien, Tsu‐Yi Chao, Tsang‐Wu Liu, Ann‐Lii Cheng, Pei‐Jer Chen – 26 February 2008 – Lamivudine is effective to control hepatitis B virus (HBV) reactivation in HBV‐carrying cancer patients who undergo chemotherapy, but the optimal treatment protocol remains undetermined.